Bulletin
Investor Alert

Landos Biopharma Inc.

NAS: LABP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 7, 2021, 4:00 p.m.

/zigman2/quotes/224337277/composite

$

10.46

Change

0.00 0.00%

Volume

Volume 7

Quotes are delayed by 20 min

/zigman2/quotes/224337277/composite

Previous close

$ 10.83

$ 10.46

Change

-0.37 -3.42%

Day low

Day high

$10.35

$10.98

Open

52 week low

52 week high

$8.82

$16.99

Open

Company Description

Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. It also offer...

Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. It also offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.

Valuation

Efficiency

Income Per Employee

-913,455.00

Liquidity

Current Ratio

2.58

Quick Ratio

2.58

Cash Ratio

2.55

Profitability

Return on Assets

-74.60

Return on Equity

-90.69

Return on Total Capital

-92.29

Return on Invested Capital

-90.69

Capital Structure

Officers and Executives

Name Age Officer Since Title
Dr. Josep Bassaganya-Riera 46 2017 Chairman, President & Chief Executive Officer
Ms. Jyoti Chauhan 31 2018 Executive Director-Global Clinical Operations
Ms. Jennifer Collette - - Financial Director & Controller
Dr. Raquel Hontecillas 49 2017 Chief Scientific Officer
Mr. Tiago M. Girão 40 2021 Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/08/2021 Perceptive Advisors (Private Equity)
Director
1,771   Acquisition at $13.1 per share. 23,200
02/08/2021 Perceptive Advisors (Private Equity)
Director
86,671   Acquisition at $12.53 per share. 1,085,987
02/08/2021 Perceptive Advisors (Private Equity)
Director
34,611   Acquisition at $11.38 per share. 393,873
02/08/2021 Perceptive Advisors (Private Equity)
Director
1,771   Acquisition at $13.1 per share. 23,200
02/08/2021 Perceptive Advisors (Private Equity)
Director
86,671   Acquisition at $12.53 per share. 1,085,987
02/08/2021 Perceptive Advisors (Private Equity)
Director
34,611   Acquisition at $11.38 per share. 393,873
02/08/2021 Perceptive Advisors (Private Equity)
Director
1,250,000   Acquisition at $16 per share. 20,000,000
02/08/2021 Perceptive Advisors (Private Equity)
Director
1,250,000   Acquisition at $16 per share. 20,000,000
02/08/2021 Perceptive Advisors (Private Equity)
Director
13,369,728   Derivative/Non-derivative trans. at $0 per share. 0
02/08/2021 Perceptive Advisors (Private Equity)
Director
1,770,600   Derivative/Non-derivative trans. at $0 per share. 0
02/08/2021 Perceptive Advisors (Private Equity)
Director
2,857,795   Derivative/Non-derivative trans. at $0 per share. 0
02/08/2021 Perceptive Advisors (Private Equity)
Director
2,857,795   Derivative/Non-derivative trans. at $0 per share. 0
02/08/2021 Perceptive Advisors (Private Equity)
Director
2,941,769   Derivative/Non-derivative trans. at $0 per share. 0
02/08/2021 Perceptive Advisors (Private Equity)
Director
2,941,769   Derivative/Non-derivative trans. at $0 per share. 0
02/08/2021 RTW Investments LP
3,650,722   Derivative/Non-derivative trans. at $0 per share. 0
02/05/2021 Perceptive Advisors (Private Equity)
Director
27,453   Acquisition at $11.14 per share. 305,826
02/05/2021 Perceptive Advisors (Private Equity)
Director
27,453   Acquisition at $11.14 per share. 305,826
/news/latest/company/us/labp

MarketWatch News on LABP

  1. Landos Biopharma started at outperform with $33 stock price target at Raymond James

    9:33 a.m. March 1, 2021

    - Tomi Kilgore

  2. Landos Biopharma started at neutral with $17 stock price target at J.P. Morgan

    9:25 a.m. March 1, 2021

    - Tomi Kilgore

  3. Bausch Health and Landos Biopharma See Activist Action

    10:30 p.m. Feb. 26, 2021

    - Barron's Online

  4. The Biotech IPO Wave Continues. 7 Stocks That Hit the Market.

    6:26 p.m. Feb. 5, 2021

    - Barron's Online

  5. A Busy Day for Biotech IPOs

    6:56 p.m. Feb. 4, 2021

    - Barron's Online

/news/nonmarketwatch/company/us/labp

Other News on LABP

  1. 10-K: LANDOS BIOPHARMA, INC.

    5:09 p.m. March 31, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  2. Wall Street Breakfast: The Week Ahead

    8:21 a.m. Feb. 28, 2021

    - Seeking Alpha

  3. Landos Biopharma Begins $100 Million IPO Push

    4:44 p.m. Jan. 22, 2021

    - Seeking Alpha

At a Glance

Landos Biopharma, Inc.

1800 Kraft Drive

Suite 216

Blacksburg, Virginia 24060

Phone

1 5402182232

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

N/A

Net Income

$-30.14M

Employees

33.00

Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.